BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34873466)

  • 1. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.
    Staley A; Tucker K; Yin Y; Zhang X; Fan Y; Zhang Y; Fang Z; Sun W; Suo H; Zhao X; Zhao Z; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
    Am J Cancer Res; 2021; 11(11):5374-5387. PubMed ID: 34873466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.
    Pierce SR; Fang Z; Yin Y; West L; Asher M; Hao T; Zhang X; Tucker K; Staley A; Fan Y; Sun W; Moore DT; Xu C; Tsai YH; Parker J; Prabhu VV; Allen JE; Lee D; Zhou C; Bae-Jump V
    J Exp Clin Cancer Res; 2021 Feb; 40(1):61. PubMed ID: 33557912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer.
    Tucker K; Yin Y; Staley SA; Zhao Z; Fang Z; Fan Y; Zhang X; Suo H; Sun W; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
    Am J Cancer Res; 2022; 12(2):521-536. PubMed ID: 35261784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer
    Zhang Y; Huang Y; Yin Y; Fan Y; Sun W; Zhao X; Tucker K; Staley A; Paraghamian S; Hawkins G; Prabhu V; Allen JE; Zhou C; Bae-Jump V
    Front Oncol; 2020; 10():577141. PubMed ID: 33194693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.
    Paraghamian SE; Qiu J; Hawkins GM; Zhao Z; Sun W; Fan Y; Zhang X; Suo H; Hao T; Prabhu VV; Allen JE; Zhou C; Bae-Jump V
    Cancer Biol Ther; 2023 Dec; 24(1):2202104. PubMed ID: 37069726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer.
    Fan Y; Wang J; Fang Z; Pierce SR; West L; Staley A; Tucker K; Yin Y; Sun W; Kong W; Prabhu V; Allen JE; Zhou C; Bae-Jump VL
    Front Oncol; 2022; 12():789450. PubMed ID: 35372029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of NT-1044, a Novel AMPK Activator, on Endometrial Cancer Cell Proliferation, Apoptosis, Cell Stress and
    Roque DR; Zhang L; Wysham WZ; Han J; Sun W; Yin Y; Livingston JN; Batchelor KW; Zhou C; Bae-Jump VL
    Front Oncol; 2021; 11():690435. PubMed ID: 34422646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.
    Guo H; Kong W; Zhang L; Han J; Clark LH; Yin Y; Fang Z; Sun W; Wang J; Gilliam TP; Lee D; Makowski L; Zhou C; Bae-Jump VL
    Am J Cancer Res; 2019; 9(10):2170-2193. PubMed ID: 31720081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
    Przystal JM; Cianciolo Cosentino C; Yadavilli S; Zhang J; Laternser S; Bonner ER; Prasad R; Dawood AA; Lobeto N; Chin Chong W; Biery MC; Myers C; Olson JM; Panditharatna E; Kritzer B; Mourabit S; Vitanza NA; Filbin MG; de Iuliis GN; Dun MD; Koschmann C; Cain JE; Grotzer MA; Waszak SM; Mueller S; Nazarian J
    Neuro Oncol; 2022 Sep; 24(9):1438-1451. PubMed ID: 35157764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.
    Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
    Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells
    El-Soussi S; Hanna R; Semaan H; Khater AR; Abdallah J; Abou-Kheir W; Abou-Antoun T
    Front Pediatr; 2021; 9():693145. PubMed ID: 34422720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
    Bonner ER; Waszak SM; Grotzer MA; Mueller S; Nazarian J
    Neuro Oncol; 2021 Apr; 23(4):542-556. PubMed ID: 33336683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro.
    Fang Z; Wang J; Clark LH; Sun W; Yin Y; Kong W; Pierce SR; West L; Sullivan SA; Tran AQ; Prabhu VV; Zhou C; Bae-Jump V
    Am J Cancer Res; 2018; 8(8):1551-1563. PubMed ID: 30210923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Antiproliferative Activity of Novel Imipridone-Ferrocene Hybrids with Triazole and Alkyne Linkers.
    Czuczi T; Murányi J; Bárány P; Móra I; Borbély A; Csala M; Csámpai A
    Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
    Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.